Mantovani F, Mascheroni E, Dal Prà M L, Montanari E, Mandressi A, Austoni E, Pisani E
Arch Ital Urol Nefrol Androl. 1989 Sep;61(3):243-8.
Thirty-three patients suffering from acute, subacute or chronic prostatovesiculitis were admitted to an open, non comparative trial. Enoxacin was administered at the daily dosage of 400 mg every 12 hours for 10 days starting from the enrollment. A second cycle of treatment was performed if cure was not obtained with the first cycle. Treatment efficacy was established by assessing patient symptoms related to the infection, such as pollakiuria and dysuria, consistency and volume of prostate and spermatic vesicles (evaluated by rectal examination and transrectal ultra-sonography); bacterioscopical and bacteriological evaluations of prostate/vesicles secretion with sensitivity testing were also carried out. All observations were collected at baseline, 5 and 30 days after the end of the first cycle and 5 days after the end of the 2nd cycle of treatment. After the first cycle of treatment, cure was obtained in 22 subjects (67%) and clinical improvement in 24 (73%). All but one patients still infected at the end of the first treatment period, showed improvement (5; 45.5%) or cure (6; 54.5%). The end of the second cycle None of the 22 patients cured with one cycle of treatment relapsed within 30 days after the end of treatment, confirming they really achieved cure. Side effects were observed only in 1 case (mild vertigo); no drop outs were observed. These results suggest that enoxacin may be successfully used in the treatment of prostato-vesiculitis.
33例患有急性、亚急性或慢性前列腺精囊炎的患者进入一项开放的、非对照试验。从入组开始，依诺沙星以每12小时400mg的日剂量给药，持续10天。如果第一个疗程未治愈，则进行第二个疗程的治疗。通过评估与感染相关的患者症状来确定治疗效果，如尿频和排尿困难、前列腺和精囊的质地和体积（通过直肠检查和经直肠超声评估）；还对前列腺/精囊分泌物进行了细菌学和细菌学评估及药敏试验。所有观察数据均在基线、第一个疗程结束后5天和30天以及第二个疗程结束后5天收集。第一个疗程治疗后，22名受试者（67%）治愈，24名（73%）临床症状改善。在第一个治疗期结束时仍未治愈的患者中，除1例患者外，其余患者均有改善（5例；45.5%）或治愈（6例；54.5%）。第二个疗程结束后，接受一个疗程治疗治愈的22例患者在治疗结束后30天内均未复发，证实他们确实实现了治愈。仅1例出现副作用（轻度眩晕）；未观察到退出试验的情况。这些结果表明，依诺沙星可成功用于治疗前列腺精囊炎。
